Roche Holding AG
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 800
- Registration Number
- NCT04660344
- Locations
- πΊπΈ
Sansum Clinic, Santa Barbara, California, United States
πΊπΈTexas Oncology-Medical City Dallas, Dallas, Texas, United States
π¨π¦Sunnybrook Research Institute, Toronto, Ontario, Canada
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT04657302
- Locations
- π¨π³
Tianjin Cancer Hospital, Tianjin, China
π¨π³Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology, Guangzhou City, China
π¨π³Beijing Cancer Hospital, Beijing, China
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
- Conditions
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 442
- Registration Number
- NCT04657289
- Locations
- π¦π·
Centro OftalmolΓ³gico Dr. Charles S.A., Capital Federal, Argentina
π¦π·Oftalmos, Capital Federal, Argentina
π¦π·Grupo Laser Vision, Rosario, Argentina
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition
- Conditions
- Interventions
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT04654468
- Locations
- π¨π³
Tianjin Medical University General Hospital, Tianjin, China
π¨π³Guangdong General Hospital, Guangzhou, China
π¨π³West China Hospital, Sichuan University, Chengdu, China
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1
- Registration Number
- NCT04644315
- Locations
- πΊπΈ
Science 37-Cannon; Dept 002-Cannon, Culver City, California, United States
πΊπΈScience 37-Basem; Dept 004- Basem, Culver City, California, United States
πΊπΈScience 37, Inc, Culver City, California, United States
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT04642365
- Locations
- π§πͺ
Cliniques Universitaires St-Luc, Bruxelles, Belgium
π¨π¦The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
π¦πΊPeter Maccallum Cancer Institute; Clinical Trial Unit, Melbourne, Victoria, Australia
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 285
- Registration Number
- NCT04639050
- Locations
- πΊπΈ
Optimus U Corp, Miami, Florida, United States
πΊπΈConquest Research, LLC, Winter Park, Florida, United States
πΊπΈQuest Research Institute, Farmington Hills, Michigan, United States
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT04629248
- Locations
- πΊπ¦
Regional Clinical Hospital n.a I.I. Mechnicov, Dnipropetrovsk, Ukraine
πΊπ¦Ternopil University Hospital, Ternopil, Kherson Governorate, Ukraine
πΊπΈNephrotex Research Group, Dallas, Texas, United States
Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT04622228
- Locations
- π¨π³
Cancer Hospital , Chinese Academy of Medical, Beijing City, China
π¨π³West China Hospital - Sichuan University, Chengdu City, China
π¨π³Second Affiliated Hospital of Third Military Medical University, Chongqing, China
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 542
- Registration Number
- NCT04619797
- Locations
- π§πͺ
Vitaz, Sint Niklaas, Belgium
π«π·CHU Strasbourg - Nouvel Hopital Civil, Strasbourg, France
π―π΅The Cancer Institute Hospital of JFCR, Tokyo, Japan